SL Science Holding Ltd
No enriched coverage for $SLBT in the last 7 days.
No SEC Form 4 filings for $SLBT in the last 30 days.
See all $SLBT insider activity →NetApp (NTAP) shares dropped 8.2% in pre-market trading despite beating Q1 earnings and revenue estimates. Other stocks moving lower include Ultragenyx (RARE), Methode Electronics (MEI), and Hewlett Packard Enterprise (HPE).
SL Science Holding Limited (SLBT) filed a Master Drug File (MDF) with the FDA for exosomes derived from Gamma Delta T (GDT) cells, which are being developed to treat brain and pancreatic cancers. The filing was made by JY BioMed Co Ltd, an investor and IP rights holder. SLBT's stock closed at $2.64 on Thursday, down to $2.58 in afterhours trading.
SL Science (NASDAQ: SLBT) announced that JY BioMed filed a new FDA Drug Master File (DMF) for GDT cell-derived exosomes, expanding regulatory documentation. This milestone covers exosomes and GDT cells, potentially streamlining future regulatory processes. The exosomes may address delivery challenges in oncology, including crossing the blood-brain barrier for brain cancer treatment.
Recent SLBT coverage spans market movers, regulation and earnings.
Recent volatility persists.
Potential catalyst for future approvals and partnership interest.
The DMF reduces future CMC bottlenecks, potentially accelerating downstream clinical programs and improving investor sentiment.
This reads more like a speculative post-listing move than a fundamentals-driven catalyst.
FDA orphan drug designation review is a positive regulatory milestone that can improve development incentives, but it is not approval and timing remains uncertain.
AlphAI scores every news story that mentions SLBT with an AI model for sentiment and relevance, and aggregates insider trades from SL Science Holding Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
NetApp (NTAP) shares dropped 8.2% in pre-market trading despite beating Q1 earnings and revenue estimates. Other stocks moving lower include Ultragenyx (RARE), Methode Electronics (MEI), and Hewlett Packard Enterprise (HPE).
3 min readSL Science Holding Limited (SLBT) filed a Master Drug File (MDF) with the FDA for exosomes derived from Gamma Delta T (GDT) cells, which are being developed to treat brain and pancreatic cancers. The filing was made by JY BioMed Co Ltd, an investor and IP rights holder. SLBT's stock closed at $2.64 on Thursday, down to $2.58 in afterhours trading.
1 min readSL Science (NASDAQ: SLBT) announced that JY BioMed filed a new FDA Drug Master File (DMF) for GDT cell-derived exosomes, expanding regulatory documentation. This milestone covers exosomes and GDT cells, potentially streamlining future regulatory processes. The exosomes may address delivery challenges in oncology, including crossing the blood-brain barrier for brain cancer treatment.
2 min readBiotech gainers on Monday included Universe Pharmaceuticals (UPC), which reported six-month ended March 31, 2026 revenue of $9.03 million and net loss of $1.55 million, and shares rose about 99% to $6.48. Cumberland Pharma (CPIX) rose over 38% ahead of Q2 results after a $100 million branded portfolio sale. Autolus (AUTL) gained about 22% on preliminary Q2 Aucatzyl net product revenue of about $45 million. Other movers included Pulmonx (LUNG), SL Science (SLBT), CAMP4 (CAMP), and Beyond Air (XAI
3 min readSL Science Holding Limited (Nasdaq: SLBT) said it submitted an FDA Orphan Drug Designation request for its Vdelta2+ Gamma Delta T cell therapy to treat glioblastoma multiforme (GBM). The FDA’s OOPD acknowledged receipt and is reviewing additional files. The company’s licensor JY BioMed will present related preclinical data at WCP 2026.
4 min readSL Science Holding Limited (formerly SL BIO Ltd.) began trading on Nasdaq as SLBT in mid-June 2026 after a SPAC merger with Horizon Space Acquisition II Corp. The company develops gamma delta T cell and gene therapies for solid tumors. Shares have swung roughly $3.00–$14.50 (52-week range) with >30% intraday moves; the deal valued equity at ~$5.568B and included a $7.8M PIPE.
7 min readSL Science Holding Limited (formerly SL BIO Ltd.) began trading on Nasdaq Global Market under ticker SLBT on June 15 after completing a SPAC merger with Horizon Space Acquisition II Corp. Shares rose ~34% to close at $5.99. The deal valued the combined entity at about $5.6B, funding gamma delta T-cell therapies and other cell/gene and exosome programs.
4 min readBiotech gainers included SL Science (SLBT), up 34.61% to $5.99 after Nasdaq trading began June 15; Chemomab (CMMB), up 33.53% to $2.27 as Phase 3 preparations for Nebokitug in primary sclerosing cholangitis continue; Propanc (PPCB), up 22.92% to $1.77 after a $500k buyback authorization. Also: VERAXA (VRXA) +18.26% to $2.04 with ATUM support; Tectonic (TECX) +15.85% to $37.93 ahead of Phase 2/1 catalysts; Aura (AURA) +15.01% to $7.74 ahead of bel-sar data; SELLAS (SLS) +12.89% to $14.98 with REG
7 min readSL Science Holding Limited (Nasdaq: SLBT) reported full-year 2025 results for the year ended Dec. 31, 2025. Net revenue fell 35% to about $2.20M from $3.36M, while net loss widened to about $3.82M from $1.19M. The company cited a Taiwan wholesale transition and higher G&A costs. It also said a $7.8M PIPE supported its Nasdaq Global Market listing after a business combination.
6 min read
